Bristol-Myers Squibb announces global collaboration with leading academic institutions
Bristol-Myers Squibb Company announced the formation of the International Immuno-Oncology Network (II-ON), a global...
Lundbeck’s Lu AE58054 meets primary endpoint
H. Lundbeck A/S today announced that Lu AE58054 has met its primary endpoint in...
Thioridazine, successfully kills cancer stem cells in the human
A team of scientists at McMaster University has discovered a drug, thioridazine, successfully kills...
Innovative public-private collaboration launches to tackle antibiotic research
GlaxoSmithKline and AstraZeneca welcomed the launch of a pioneering approach to antibiotic research in Europe...
Bayer’s Regorafenib submitted for EU and US marketing authorization
Bayer HealthCare has submitted a Marketing Authorization Application to the European Medicines Agency and...
One million signatures needed to call upon World Health Organisation
The 1 Mission 1 Million - Getting to the Heart of Stroke initiative is...
Biomarker predicts response to cancer treatment
VIB researcher Diether Lambrechts, associated with KU Leuven, has discovered a biomarker that might...
FDA approves generic versions of blood thinner Plavix
The U.S. Food and Drug Administration approved generic versions of the blood thinning drug...
Amgen’s BiTE® antibody blinatumomab achieved high rate of complete response
Amgen announced updated results from a Phase 2 study that showed treatment with blinatumomab...
In drug-approval race, US FDA ahead of Canada, Europe
The U.S. Food and Drug Administration (FDA) generally approves drug therapies faster and earlier...
